Impact of Experimental Development of Arterial Hypertension and Dyslipidemia on Intravascular Activity of Rats’ Platelets

Great interest is shown by researchers to functional and rheological features of basic regular blood elements. Platelets are among them and take the most active part in hemostasis at rather wide-spread nowadays cardio-vascular and metabolic diseases. The aim is to analyze dynamics’ strengthening of platelets' intravascular activity of rats in conditions of experimental consequent development of arterial hypertension and dyslipidemia. The study used 68 male-rats of Vistar line at the age of 2.5-3 months. Control group was composed of 33 animals. Experimental animals (35 rats) were developed at first – arterial hypertension (usage of cardioangiol pathogenic diet for 2 weeks and impact of cold at the end) and then - dyslipidemia (application of rich in calories diet at lowering of motor activity). The rats from experimental group were examined 5 times during the research. The rats from control group were examined twice - at the beginning and at the end of the experiment. While examining experimental and control rats we applied biochemical, hematological and statistical methods of investigation. At consequent arterial hypertension and dyslipidemia development experimental rats had gradual strengthening of lipids' peroxidation processes in plasma (acylhydroperoxides increased in 2.1 times) and platelets (acyl hydroperoxides increased in 1.4 times). Already at arterial hypertension development rats' blood was noted to have lowering of discocytes' quantity on 5.9%, deepening during the further dyslipidemia development on 7.4% more, and reaching 24.6±0.13%. This process was accompanied by gradual increase of activated platelets' sum on 75.7% during the whole period of investigation. The number of small, middle and large platelet aggregates, freely circulating in blood during modeling of double pathology, gradually increased in 2.8 times and in 10.3 times, respectively. Control rats had stable normal level of relevant biochemical and hematological characteristics. Subsequent development of at first arterial hypertension and then – dyslipidemia in rats gradually weakened their antioxidant protection of blood plasma and platelets and strengthened POL processes in them. It also strengthened lipids' peroxidation in them. Developing abnormalities gradually strengthened intravascular platelets' activity and their aggregative ability in experimental animals. The created model allowed tracking the earliest symptoms of strengthening of platelets’ intravascular activity against the background of AH and dyslipidemia development.

[1]  Makurina On,et al.  Platelet-Activity Dependence on the Age of Rats with Experimental Dyslipidemia , 2016 .

[2]  M. A. Gilinsky,et al.  Neuroendocrine profiling in inherited stress-induced arterial hypertension rat strain with stress-sensitive arterial hypertension. , 2007, The Journal of endocrinology.

[3]  I. Medvedev,et al.  [Platelet Activity in Patients With Third Degree Arterial Hypertension and Metabolic Syndrome]. , 2016, Kardiologiia.

[4]  I. Medvedev,et al.  RAPID ASSESSMENT OF AGGREGATION ABILITIES AND SURFACE PROPERTIES OF PLATELETS AND RED BLOOD CELLS , 2016 .

[5]  Артериальная гипертония,et al.  Fluvastatin effects on blood cell aggregation in patients with arterial hypertension and dyslipidemia , 2015 .

[6]  I. Medvedev,et al.  Platelet aggregation in clinically healthy persons of the second coming-of-age living in the Kursk oblast , 2015, Advances in Gerontology.

[7]  A. Markel,et al.  Stress and arterial hypertension: ISIAH rat strain , 2015 .

[8]  I. Medvedev,et al.  [The aggregation capacity of neutrophils in patients with arterial hypertension and dyslipidemia treated with fluvastatin]. , 2015, Klinicheskaia meditsina.

[9]  I. Medvedev,et al.  [Erythrocyte aggregation in patients with arterial hypertension and dyslipidemia treated with pravastatin]. , 2014, Klinicheskaia meditsina.

[10]  I. Medvedev,et al.  [The use of verospiron and the degree of platelet aggregation in arterial hypertension with abdominal obesity]. , 2014, Klinicheskaia meditsina.

[11]  I. Medvedev,et al.  [Effect of therapy with diuretics on the functional activity of platelets in patients with arterial hypertension and abdominal obesity]. , 2012, Klinicheskaia meditsina.

[12]  I. Medvedev,et al.  [Dynamics of microrheologic properties of erythrocytes in patients with arterial hypertension and dyslipidemia treated with atorvastatin]. , 2012, Klinicheskaia meditsina.

[13]  I. Medvedev,et al.  [Pathogenetic aspects of arterial hypertension in metabolic syndrome]. , 2011, Klinicheskaia meditsina.

[14]  I. Medvedev,et al.  [Primary hemostasis activity in patients with arterial hypertension and impaired glucose tolerance treated with trandolapril]. , 2011, Klinicheskaia meditsina.

[15]  I. Medvedev,et al.  [Dynamics of primary hemostasis activity in patients with arterial hypertension and metabolic syndrome treated with candesartan]. , 2011, Klinicheskaia meditsina.

[16]  E. Nalivaiko.  Frontiers In Research Review: Stress and Hypertension Animal models of psychogenic cardiovascular disorders: what we can learn from them and what we cannot , 2011 .

[17]  I. Medvedev,et al.  [Pathogenetic aspects of hypertension in case of metabolic syndrome]. , 2010, Voenno-meditsinskii zhurnal.

[18]  Medvedev In,et al.  Effect of lovastatin on adhesive and aggregation function of platelets in patients with arterial hypertension and dislipidemia , 2010 .

[19]  I. Medvedev,et al.  Activity of Platelet Hemostasis in Children with Spinal Deformities , 2010, Bulletin of Experimental Biology and Medicine.

[20]  I. Medvedev,et al.  [Effect of eprosartan on thrombocytes aggregative capacity in patients with arterial hypertension and metabolic syndrome]. , 2008, Klinicheskaia meditsina.

[21]  I. Medvedev,et al.  [Comparative evaluation of the influence of sulfhydryl and phosphate ACE inhibitors on thrombocyte aggregation in patients suffering from atrerial hypertension with metabolic syndrome]. , 2007, Klinicheskaia meditsina.

[22]  I. Medvedev,et al.  [The antiaggregation activity of the vascular wall in patients suffering from arterial hypertension with metabolic syndrome]. , 2007, Klinicheskaia meditsina.

[23]  I. Medvedev,et al.  [The influence of hypocaloric diet on thrombocyte rheology in patients with metabolic syndrome]. , 2006, Klinicheskaia meditsina.

[24]  I. Medvedev,et al.  [Correction of thrombocyte hemostasis and biological age reduction in metabolic syndrome]. , 2005, Klinicheskaia meditsina.

[25]  I. Medvedev,et al.  [Effects of lisinopril on platelet aggregation in patients with arterial hypertension with metabolic syndrome]. , 2004, Kardiologiia.